DealÜP: Hemerion & Capital Cell

Don't miss this dealÜP with Hemerion!
This time, we have Maximilien Vermandel, CEO and founder of Hemerion, who tell us about the disruptive technology they are developing.
Hemerion is a clinical-stage healthtech company developing novel cancer therapies. Its first "best-in-class" drug-device therapeutic is dedicated to Brain Cancer, with a promising strategy to significantly improve the outcomes in Glioblastoma, the most common and aggressive brain cancer.
In addition, we have the presence of Alan Ezrin, who explains why he invests in Hemerion and believes this is a game changer.